共 151 条
[1]
Tovey SM(2009)Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours Br J Cancer 100 680-683
[2]
Brown S(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
[3]
Doughty JC(2018)Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update J Clin Oncol 36 2105-2122
[4]
Mallon EA(2020)HER2-low breast cancer: pathological and clinical landscape J Clin Oncol 38 1951-1962
[5]
Cooke TG(2023)The HER2-low revolution in breast oncology: steps forward and emerging challenges Ther Adv Med Oncol 15 17588359231152842-20
[6]
Edwards J(2022)Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer N Engl J Med 387 9-2064
[7]
Slamon DJ(2011)HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care Clin Cancer Res 17 2055-3023
[8]
Leyland-Jones B(2013)Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient Ann Oncol 24 3017-580
[9]
Shak S(2018)Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis J Natl Cancer Inst 110 568-2506
[10]
Fuchs H(2020)Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution Mod Pathol 33 2499-43